Zoetis names Saccaro CFO, chief operating officer. The basics: * Saccaro will join Zoetis as CFO, COO Aug. 17 * Newly created role includes oversight of manufacturing, supply operations * Current CFO will serve as special advisor to the CEO through early 2027 * Zoetis reported $2.5B in Q2 2026 revenue Zoetis Inc. has appointed James (Jay) Saccaro as executive vice president, chief financial officer and chief operating officer, effective Aug. 17, 2026. The Parsippany-headquartered animal health company announced the new hire Aug. 6. Zoetis also said it's a newly created position. Saccaro will take over responsibilities from Wetteny Joseph, who will remain with the company as a special advisor to CEO Kristin Peck until early 2027. According to Zoetis' executive team page, Joseph's title is executive vice president and CFO. Saccaro joins Zoetis from GE HealthCare, where he most recently served as vice president and CFO. At that company, Saccaro led initiatives across sectors such as finance, accounting, new product planning, R&D prioritization and capital allocation, according to Zoetis. Prior to GE HealthCare, Saccaro held various financial leadership positions at Baxter International Inc., Hillrom, Clear Channel Communications and The Walt Disney Co., according to his LinkedIn profile. New position. "We are excited to welcome Jay to Zoetis as we prepare for our next wave of innovation-driven growth," Peck said in a statement. "Jay brings a unique combination of skills to this newly created leadership position. He is a seasoned finance executive with 12 years of CFO experience at some of the world's leading healthcare companies and has proven expertise in successfully developing and executing company-wide strategic initiatives." Peck added that responsibilities of the expanded position will include: * Strengthening the company's global manufacturing and supply operations * Enhancing supply chain and distribution performance * Driving greater operational agility Saccaro said he was "thrilled to join the world's leading animal health company," adding that there was "tremendous runway to build on" Zoetis' legacy. "From the company's deep innovation pipeline to its products that have built and defined categories in the industry, Zoetis is an exceptional business grounded in a deep commitment to setting new standards for the future of animal care." 'A challenging quarter' Peck also thanked Joseph "for his strong leadership, partnership, and many important contributions since joining the company five years ago." In his final earnings update posted on LinkedIn Aug. 6, Joseph said, "I want to recognize our colleagues, who remained focused on delivering for our customers despite a challenging quarter." In the video, Joseph noted that "results this quarter fell short of our expectations," adding that, on an organic operational basis, Zoetis' revenue declined 1% and adjusted net income declined 2%. The company's quarterly report noted revenue of $2.5 billion for the second quarter of 2026. Breaking down results across its U.S. and international segments: * U.S. segment revenue: $1.3 billion, decreasing 7% relative to Q2 2025 * International segment revenue: $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis compared with Q2 2025 Joseph said challenges such as declining veterinary visits and greater pet owner price sensitivity placed pressure on the companion animal industry. However, he said the company was "responding with urgency and focus." He added on the post, "I close this chapter with confidence in Zoetis' people, portfolio and pipeline. The work ahead is clear, and the company has the talent and capabilities to execute and create long-term value."

Will operational challenges continue to negatively impact Baxter's second. Baxter International (BAX) is scheduled to report second-quarter 2026 earnings before the U.S. stock market open on July 30. In the prior-year quarter, the company's earnings missed the Zacks Consensus Estimate by 16.13%. Over the past four quarters, BAX has beaten estimates in two quarters and missed them in two quarters, by an average of 3.12%. The market consensus is for revenue to be $2.84 billion, down 0.6% from the previous year. Earnings per share are expected to be $0.36, down 39% from the previous year. Its model projects that, at constant exchange rates, total revenue from continuing operations will decline 2.5% to $2.79 billion. Adjusted earnings per share are expected to decline 39% to 36 cents. Baxter expects a slight improvement in its second-quarter results, but persistent efficiency gaps, cost inflationary pressures, and the ongoing suspension of high-volume infusion pump (LVP) shipments could constrain growth. Following the release of its first-quarter results, management reiterated its full-year outlook, stating that second-quarter profits are likely to remain flat compared to the first quarter, with only a slight increase in sales, and that a more significant recovery is expected in the second half of the year. While demand remains strong in end markets across various industries, project execution challenges and difficulties in year-over-year comparisons are expected to negatively impact profitability. In the Medical Devices and Therapies (MPT) segment, performance is likely to remain mixed. The Advanced Surgical segment should continue to outperform other segments due to strong global demand for hemostatic agents and sealants, as well as significant surgical volumes. However, the Infusion Therapies and Technologies segment may remain under pressure due to factors such as ongoing suspensions of Novum LVP device shipments and installations, declining infusion pump sales, and normalization of IV infusion demand following the expansion of the distribution network impacted by Hurricane Helene last year. Management expects pump revenue to increase in the second half of the year as Spectrum technology gains traction, but higher production costs should limit performance in the second quarter. Its model projects revenue in this segment to decline 3% to $1.3 billion at constant exchange rates. The Healthcare Systems and Technologies segment is expected to face another weak quarter, offset by strong demand for patient support systems and significant capital equipment orders in the US, partly due to delays in the installation of first aid equipment. Management still expects the segment's performance to improve later this year as recently launched products, including Connex 360 and the Dynamo intelligent stretcher, begin to make a more significant contribution. Its model projects revenue for this segment to grow 2.9% to $795.1 million at constant currency rates. The pharmaceutical segment may still face challenges such as limited supply of injectables, weak global demand for inhalational anesthetics, and an unfavorable product mix. However, improved manufacturing efficiency, continued declines in order volumes, and strong growth in the formulation business should mitigate these negative factors to some extent. According to its model, at constant exchange rates, segment revenue will decline 3.6% to $609 million. Baxter may continue to face high production costs, tariff-related expenses, and inflationary pressure in the second quarter. Management expects this pressure to ease in the second half of the year as high-cost inventory is depleted, cost-cutting measures are implemented, and operating leverage improves thanks to a seasonal sales recovery. Therefore, adjusted earnings per share in the second quarter are likely to remain flat compared to the first quarter. Its model didn't predict that Baxter would beat earnings estimates this time. The likelihood of a beat increases when the earnings estimate deviation is positive and the Zacks Rank is a 1 (Strong Buy), 2 (Buy), or 3 (Hold). However, as you'll see below, this isn't the case for Baxter. Baxter (ESP) Earnings Estimate Variance: The earnings estimate deviation is the difference between the most accurate earnings forecast and the Zacks Consensus Estimate. Baxter's earnings estimate deviation is -0.99%. Use its earnings estimate deviation filter to find the best stocks to buy and sell before earnings releases. Baxter's stock price has risen 13.4% year-to-date, while the industry as a whole has fallen 22.5% over the same period. The S&P 500 has risen 9.3% over the same period. Here are a few healthcare stocks to watch because they have the right combination of factors to outperform expectations this earnings cycle. Cardinal Health (CAH) currently has an Earnings Expectations ESP of +1.24%, giving it a Zacks Rank of #2. The company is scheduled to report its fourth-quarter fiscal 2026 earnings on August 11th. The complete list of today's Zacks Rank #1 stocks can be found here. CAH's earnings have beaten expectations over the past four quarters, by an average of 10.27%. The Zacks Consensus Estimate is for CAH's fourth-quarter earnings per share to increase 16.4% year-over-year. Henry Shane Inc. (HSIC) currently has an estimated earnings consensus of +0.41%, giving it a Zacks Rank of #2. The company is scheduled to report second-quarter 2026 earnings on August 4. HSIC has beaten earnings estimates in three of the last four quarters and missed them in one, surpassing estimates by an average of 3.74%. The Zacks Consensus Estimate is for HSIC's second-quarter earnings per share to increase 10.9% year-over-year. Company A has beaten earnings estimates in three of the last four quarters and missed them in one quarter, beating the estimate by 1.61% on average. The Zacks Consensus Estimate is for Company A's earnings per share to increase 8% year-over-year in the third quarter of fiscal 2026. Five Zacks experts selected thousands of stocks they believed had the potential to grow by 100% or more in the coming months. Research Director Sheraz Mian selected one of these five stocks, believing it had the greatest explosive growth potential. This company targets millennials and Gen Z and generated nearly $1 billion in revenue in its most recent quarter. The recent share price drop represents an excellent entry point. While not all of its recommendations will be profitable, this stock has far greater potential than previous Zacks "Potential Doubler" stocks, such as Nano-X Imaging, which has risen 129.6% in just nine months. Get free access to our top picks and four other promising stocks. Want the latest recommendations from Zacks Investment Research? Download the "Top 7 Stocks for the Next 30 Days" report for free today. Click here to get this free report. Portions of market data provided by ICE Data Services. Portions of reference data provided by FactSet. Copyright (C) 2026 FactSet Research Systems Inc. Copyright (C) 2026 American Bankers Association. CUSIP database provided by FactSet Research Systems Inc. All rights reserved. SEC filings and other documents provided by Quartr. (C) 2026 TradingView, Inc. Post time: Jul-27-2026

Webinar - when the first surgery is not the last: adhesions and long-term strategy in HPB surgery. For many hepatobiliary surgeons, the success of an operation is measured by the outcome of the procedure itself. Yet for an increasing number of patients, the first operation is only one step in a much longer treatment journey. Patients with colorectal liver metastases, hepatocellular carcinoma and other complex hepatobiliary diseases frequently require staged procedures, repeat liver resections or further abdominal surgery. In these situations, postoperative adhesions can significantly influence future operative difficulty, prolong operating times, increase conversion rates and complicate subsequent surgical access. Despite their impact, adhesions often remain an under-recognised consideration during the initial surgical planning process. Recognising this important challenge, IHPBA and Baxter are partnering to present an educational webinar exploring the long-term implications of adhesions in liver surgery and practical strategies that may help optimise future surgical options. A practical, case-based discussion. Presented by Dr Francesca Ratti, Senior Staff Surgeon at the IRCCS San Raffaele Scientific Institute and Assistant Professor of Surgery at Vita-Salute San Raffaele University in Milan, the webinar will examine adhesions through real-world clinical scenarios rather than theory alone. Drawing on her extensive experience in minimally invasive liver surgery and complex hepatobiliary oncology, Dr Ratti will discuss how surgical history, disease setting and operative strategy influence both the development and consequences of adhesions. Participants will explore when adhesion prevention should become part of the surgical plan and how anti-adhesion technologies may contribute to facilitating future abdominal access in carefully selected patients. Learning from real-world data. An important feature of the webinar will be insights from the Italian Registry of Minimally Invasive Liver Resections, examining how previous surgery, whether open or minimally invasive, can affect operative complexity, conversion rates and decision-making during repeat liver procedures. The discussion will also focus on patients undergoing two-stage hepatectomy, repeat liver resections and multidisciplinary treatment pathways where future reintervention is anticipated, providing attendees with practical considerations that can be incorporated into everyday clinical practice. Practical takeaways for surgeons. By combining registry evidence, clinical reasoning and practical operative experience, this webinar aims to provide surgeons with a structured framework for: * Identifying patients at increased risk of adhesion-related challenges. * Recognising clinical situations where adhesion prevention strategies may be appropriate. * Understanding how previous open and minimally invasive surgery can influence future operative planning. * Incorporating long-term surgical strategy into decision-making for patients likely to require repeat abdominal procedures. As advances in hepatobiliary oncology continue to improve survival, more patients are living long enough to undergo multiple interventions over the course of their disease. This shift challenges surgeons to think beyond the immediate operation and consider how today's surgical decisions may affect tomorrow's opportunities. Join IHPBA and Baxter. Join IHPBA and Baxter on Thursday, 3 September 2026, for this timely webinar exploring how long-term planning and thoughtful adhesion management can help optimise outcomes for patients requiring repeat hepatobiliary surgery. Baxter is a registered trademark of Baxter International Inc. Published on Friday 24th July 2026